NCT01161940已完成1 期
A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 主要终点
- Bioequivalence based on Cmax and AUC parameters
研究概览
简要总结
This is a bioequivalence study of nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited under fasting conditions
详细描述
Open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, comparative oral bioavailability study in healthy, adult, male human subjects under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males between 18 and 55 years of age (inclusive) living in and around Ahmedabad city of western part of India.
- •Having a Body Mass Index (BMI) ≥ 18.0 kg/m2 (calculated as weight in kg/ height in m2).
- •Have no significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, ECG and X-ray recordings.
- •Able to communicate effectively with study personnel. Able to give consent for participation in the trial
排除标准
- •Known hypersensitivity or idiosyncratic reaction to nizatidine or other related drugs.
- •Any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal, or any other body system.
- •Ingestion of a medication at any time in 14 days before the start of the study. In any such case subject selection will be at the discretion of the Principal Investigator/Medical expert/co-investigator.
- •Any history or presence of asthma or nasal polyp.
- •A recent history of alcoholism (<2years) or of moderate (180 ml/day) alcohol use.
- •Smokers, who smoke more than 10 cigarettes/day or those who cannot refrain from smoking during study period.
- •The presence of clinically significant abnormal laboratory values during screening.
- •Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scan.
- •History of psychiatric disorders.
- •A history of difficulty with donating blood.
- •Donations of blood (1 unit or 450 ml) within 90 days prior to receiving the first dose of study medication. Note: Incase the blood loss is ≤ 200 L, subject may be dosed after completion of 60 days of blood donation).
- •A positive hepatitis screen including hepatitis B surface antigen, anti-HCV and anti-HAV antibodies.
- •A positive test result for HIV antibody and/or syphilis.
- •The receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study medication (Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study). (Note: If subject had participated in a study in which blood loss is ≤200 mL, subject can be dosed after completion of 60 days of previous study).
- •An unusual diet, for whatever reason (eg., low-sodium), for four weeks prior to receiving the study medication and throughout the subjects, participation in the study. In any such case subject will be at the discretion of the Principal Investigator/Medical expert/Co-investigator.
研究组 & 干预措施
Nizatidine
Experimental
Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
干预措施: Nizatidine (Drug)
Axid
Active Comparator
Axid 300 mg Capsules of Reliant Pharmaceuticals, US
干预措施: Axid (Drug)
结局指标
主要结局
Bioequivalence based on Cmax and AUC parameters
时间窗: 3 Months
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting ConditionsHealthyNCT01146028Dr. Reddy's Laboratories Limited42
已完成
1 期
Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed ConditionsHealthyNCT01065987Dr. Reddy's Laboratories Limited24
已完成
1 期
Bioequivalence Study of Dr.Reddys Laboratories Limited, Glimepiride 1 mg Tablets in Healthy Subjects Under Fed ConditionHealthyNCT01053689Dr. Reddy's Laboratories Limited44
已完成
1 期
Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting ConditionHealthyNCT01052909Dr. Reddy's Laboratories Limited44
已完成
1 期
Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting ConditionsHealthyNCT01131702Dr. Reddy's Laboratories Limited24